Home » Stocks » MGEN

Miragen Therapeutics, Inc. (MGEN)

Stock Price: $1.26 USD 0.74 (142.35%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
Pre-market: $1.10 -0.16 (-12.70%) Oct 29, 8:07 AM

Stock Price Chart

Key Info

Market Cap 71.33M
Revenue (ttm) 2.57M
Net Income (ttm) -35.83M
Shares Out 56.61M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $1.26
Previous Close $0.52
Change ($) 0.74
Change (%) 142.35%
Day's Open 1.13
Day's Range 0.82 - 1.37
Day's Volume 265,968,114
52-Week Range 0.31 - 2.27

More Stats

Market Cap 71.33M
Enterprise Value 49.54M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.61M
Float 50.43M
EPS (basic) -0.98
EPS (diluted) -0.88
FCF / Share -0.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.57M
Short Ratio 1.35
Short % of Float 3.11%
Beta 1.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 27.74
PB Ratio 1.31
Revenue 2.57M
Operating Income -35.67M
Net Income -35.83M
Free Cash Flow -32.34M
Net Cash 21.79M
Net Cash / Share 0.38
Gross Margin -1,113.69%
Operating Margin -1,387.51%
Profit Margin -1,393.50%
FCF Margin -1,257.68%
ROA -50.85%
ROE -131.22%
ROIC -613.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.20*
(233.33% upside)
Low
1.00
Current: $1.26
High
6.00
Target: 4.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue4.468.394.003.482.544.324.324.41
Revenue Growth-46.8%109.49%15.13%37%-41.25%0.09%-2.04%-
Gross Profit4.468.394.003.480.070.951.541.36
Operating Income-41.98-33.08-26.53-16.99-11.19-6.87-0.20-4.03
Net Income-41.87-32.70-26.51-17.27-11.33-6.64--7.60
Shares Outstanding31.3429.6019.240.610.540.150.010.01
Earnings Per Share-1.34-1.10-1.38-28.21-21.02-52.47-183.36-1,297.30
Operating Cash Flow-36.06-26.84-28.17-14.76-6.90-2.21-1.17-6.22
Capital Expenditures-0.08-0.45-0.25-0.25-0.12-0.27-0.01-0.09
Free Cash Flow-36.14-27.29-28.41-15.01-7.02-2.48-1.17-6.31
Cash & Equivalents26.8562.4847.4422.1010.835.120.260.16
Total Debt8.3010.309.924.791.11-26.6122.63
Net Cash / Debt18.5452.1837.5217.329.735.12-26.35-22.47
Assets30.2666.1552.4824.7612.908.093.672.78
Liabilities14.5114.8013.979.712.492.1027.5624.22
Book Value15.7551.3438.51-61.9210.415.99-23.89-21.44
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Miragen Therapeutics, Inc.
Country United States
Employees 45
CEO Lee M. Rauch

Stock Information

Ticker Symbol MGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MGEN

Description

Miragen Therapeutics, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.